[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-covid-19\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-covid-19":65},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,87,114],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100620581","phase-3-selective-serotonin-reuptake-inhibitors-in-post-covid-after-covid-19-100620581",false,"NCT07359482","sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19","sElective Serotonin reuPtake inhibitoRs In posT-covid: ESPRIT","ESPRIT","Inclusion Criteria:\n\n* Adults aged 18 to 70 years\n* Severely fatigued (CIS fatigue score ≥ 35) at screening\n* Fatigue started\u002Fincreased significantly after Covid-19 (self-declared)\n* Fatigue symptoms must be present for at least 3 months following the acute infection.\n* Self-reported confirmation of having a SARS-CoV-2 infection by: Positive SARS-CoV-2 nucleic acid amplification test (NAAT), such as PCR; Positive SARS-CoV-2 rapid diagnostic test, including home-administered tests; COVID-19 diagnosis by a medical specialist (GP or in-hospital), based on the above or other clinical test or assessments. The above information will not be verified in medical records.\n* Command of Dutch or English language to complete questionnaires\n* Able to participate in video calling.\n* Willing and able to provide informed consent\n* Allowing the trial team to exchange medical information that is relevant for the participants' safety and trial assessments with their GP and pharmacy.\n\nExclusion Criteria:\n\n* Use of medication with interaction with fluvoxamine that cannot be discontinued\n* Hospitalized in the acute phase of Covid-19\n* Psychiatric\u002Fsomatic disorders that could explain the severity of fatigue\n* Neurodegenerative disorders (i.e. M Parkinson, Multiple sclerosis, M Alzheimer)\n* Suicidality (current or recent) (according to WHO suicide screener)\n* Starting or started with other medication intended to reduce post-covid symptoms during the last 2 months\n* Pregnancy (a positive urine or serum pregnancy test) or unwilling to use standard contraception\n* Brugada- or Long QT interval syndrome\n* epilepsy, porphyria, history of severe liver impairment\n* known allergies to fluvoxamine or placebo\u002Fexcipients\n* known current alcohol or drug use problems.\n* Bleeding disorders and past medical history of bleeding gastric or duodenal ulcers or other significant bleeding disorders\n* claustrophobia (optional MRI substudy)\n* having metal implants (optional MRI substudy)\n* inability to lay still for 45 minutes (optional MRI substudy)\n* Neurotrauma\u002F large stroke or brain abnormalities interfering with image analyses (optional MRI substudy)\n* Inability to come to the Amsterdam UMC (optional MRI substudy).","ALL","18 Years","70 Years",{"count":21,"type":22},160,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Fatigue, cognitive problems, post-exertional malaise (PEM) and postural orthostatic tachycardia syndrome (POTS) are common and debilitating symptoms after COVID-19. The pathophysiology of post-COVID is not well understood and there is no established biomedical treatment. Treatment options for post-COVID are thus much needed.\n\nA promising candidate intervention is fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), that may reduce post-COVID symptoms because of its regulatory effect on the (neuro) immune system, the hypothalamic-pituitary-adrenal (HPA) axis and the tryptophan system. The investigators will randomize 160 participants to either fluvoxamine or placebo for 12 weeks.\n\nThe investigators will use advanced functional neuroimaging techniques during cognitive challenge (optional substudy) and plasma biomarkers (inflammatory markers, cortisol, serotonin, IDO-2 activity), to facilitate identifying potential mechanistic pathways of post -COVID treatment.",[28,29,30],"Post-COVID","POST-Covid 19","Post-COVID Conditions",[32,33,34,35],"post-COVID","fluvoxamine","fatigue","biomarkers","RECRUITING","2026-06-08",{"date":39,"type":40},"2026-06-09","ACTUAL",{"date":42,"type":40},"2026-06-04",{"date":44,"type":22},"2028-05-01",{"name":46,"class":47},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":68,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":82,"leadSponsor":84,"locationsCount":48},"100601455","effects-of-kneipp-hydrotherapy-in-post-covid-19-patients-100601455","NCT07110714","Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients","Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients: A Randomized Controlled Trial","HydroCoVitalB","Inclusion Criteria:\n\n* Diagnosis of Post-COVID Syndrome (ICD-10 code: U08.9)\n* Barthel-Index \\>80\n* Owning a smartphone to receive digital questionnaires and to use the measurement app for heart rate variability\n* Written informed consent\n\nExclusion Criteria:\n\n* Existing contraindications for Kneipp hydrotherapy like severe cardiovascular diseases (e.g., decompensated heart failure, unstable angina pectoris, acute myocardial infarction), severe venous diseases (e.g., acute deep vein thrombosis of the leg), severe neurological diseases (e.g., uncontrolled epilepsy)\n* Prior regular practice of Kneipp applications",{"count":58,"type":22},30,[60],"NA","This randomized controlled study evaluates the effects of cold water hydrotherapy in patients with Post-COVID Syndrome. The primary aim is to assess changes in quality of life compared to an usual care setting without hydrotherapy treatment.",[63,64,65,66,67],"Post COVID-19 Condition","Post COVID-19 Condition (PCC)","Post COVID-19","Post COVID-19 Syndrome","Long COVID-19 Syndrome",[69,70,71,72,73,74,75,76,77],"therapy","intervention","hydrotherapy","Kneipp","balneotherapy","quality of life","PCC","long COVID","post COVID-19","2025-12-01",{"date":80,"type":40},"2025-12-02",{"date":78,"type":40},{"date":83,"type":22},"2027-10-31",{"name":85,"class":86},"Eggensberger OHG","INDUSTRY",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":97,"briefSummary":98,"conditions":99,"keywords":103,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":111,"leadSponsor":112,"locationsCount":48},"100594012","effects-of-hydrotherapy-during-post-covid-19-rehabilitation-100594012","NCT07013903","Effects of Hydrotherapy During Post-COVID-19 Rehabilitation","Effects of Kneipp Hydrotherapy During Inpatient Post-Covid-19 Rehabilitation: A Randomized Controlled Trial","HydroCoVital A","Inclusion Criteria:\n\n* Diagnosis of Post-COVID Syndrome (ICD-10 code: U08.9)\n* Barthel-Index \\>80\n* Referred to the reference center for Post-COVID rehabilitation\n* Owning a smartphone to receive digital questionnaires and to use the measurement app for heart rate variability\n* Written informed consent\n\nExclusion Criteria:\n\n* Existing contraindications for Kneipp hydrotherapy like severe cardiovascular diseases (e.g., decompensated heart failure, unstable angina pectoris, acute myocardial infarction), severe venous diseases (e.g., acute deep vein thrombosis of the leg), severe neurological diseases (e.g., uncontrolled epilepsy)\n* Prior regular practice of Kneipp applications",{"count":96,"type":22},50,[60],"This randomized controlled study evaluates the effects of cold water hydrotherapy as an adjunct to standard rehabilitation in patients with Post-COVID Syndrome. The primary aim is to assess changes in quality of life compared to standard rehabilitation alone.",[100,29,101,102],"Post-COVID \u002F Long-COVID","Post COVID Syndrome","Post-COVID Condition",[104,69,28,105,70,71,72,73,106,74],"rehabilitation","Long COVID","Post-COVID condition","2025-08-21",{"date":109,"type":40},"2025-08-28",{"date":107,"type":40},{"date":83,"type":22},{"name":113,"class":47},"Schön Klinik Berchtesgadener Land",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":122,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":4},"100567906","changes-in-electrocardiographic-ecg-ventricular-repolarization-and-transthoracic-impedance-cardiography-icg-parameters-in-patients-with-covid-19-and-after-the-disease-persistence-and-prognostic-significance-of-these-changes-100567906","NCT06674278","Changes in Electrocardiographic (ECG) Ventricular Repolarization and Transthoracic Impedance Cardiography (ICG) Parameters in Patients with COVID-19 and After the Disease: Persistence and Prognostic Significance of These Changes","Inclusion Criteria:\n\n* Patient was hospitalized and treated in LUHS Kaunas Hospital for acute COVID-19 2 years ago (starting from 2022 January 1st).\n* During hospitalization COVID-19 was verified with PCR test from nasopharyngeal swab.\n\nExclusion Criteria:\n\n* COVID-19 was not verified with PCR test from nasopharyngeal swab.\n* Patients who are unable to give informed consent for participation in study; vulnerable individuals: students if their participation is related to their studies, employees of healthcare institutions subordinate to the researcher, residents of social care institutions, and soldiers during their active military service.\n* Patients with an implanted pacemaker or cardioverter-defibrillator.\n* Patients whose permanent residence is not in Lithuania and who are not Lithuanian citizens.\n* Patients for whom it is not possible to perform ECG and ICG tests due to various circumstances.\n* Pregnant individuals (including individuals who were pregnant during the disease).",{"count":121,"type":22},215,"OBSERVATIONAL","The aim of this study is to determine the relationship between changes in resting electrocardiography (ECG) ventricular repolarization parameters, transthoracic impedance cardiography (ICG) parameters, and COVID-19, to assess the relationship between ECG changes after COVID-19 and heart rhythm disorders (arrhythmias), cardiovascular events (the onset and exacerbation of cardiovascular diseases), the persistence of changes two years after the illness, and to identify prognostic ventricular repolarization parameters in patients with and after COVID-19.\n\nIt is expected that the results obtained during the study will help predict long-term cardiovascular complications in these patients, aiming to prevent them by providing recommendations for the long-term monitoring of individuals who have recovered from COVID-19. Additionally, the investigators hope to propose a new ECG ventricular repolarization parameter that could be used in the future for prognostic assessment in patients with other diseases as well.",[65,125,126,127],"Ventricular Repolarization","Arrhythmias","Impedance Cradiography","NOT_YET_RECRUITING","2024-11-03",{"date":131,"type":40},"2024-11-05",{"date":133,"type":22},"2024-11",{"date":135,"type":22},"2027-01",{"name":137,"class":47},"Lithuanian University of Health Sciences"]